Clinical Trial Update: Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the immunogenicity of the recombinant zoster vaccine in patients with multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Shingles
• Zoster

Drugs mentioned

• Recombinant Zoster Vaccine (gZV)

Snippet

Sponsor: Prof Patrice Lalive | Conditions: Shingles, Zoster | Phase 4 | Status: RECRUITING